SCHEMBL1436331

SCHEMBL1436331

Cc1cc2ccccc2c(=O)n1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 2/20 0.44
FEN1 P39748 2/20 0.44
ERCC4 Q92889 2/20 0.44
KDM4E B2RXH2 11/20 0.44
HSD17B10 Q99714 7/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 5/20 0.44
GAA P10253 3/20 0.44
POLB P06746 2/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 2/20 0.44
PKM P14618 1/20 0.44
CASP1 P29466 1/20 0.44
GALK1 P51570 1/20 0.44
BLM P54132 1/20 0.44
CASP7 P55210 1/20 0.44
SAE1 Q9UBE0 1/20 0.44
UBA2 Q9UBT2 1/20 0.44
TSHR P16473 1/20 0.42
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13180854 0.78 HSD17B10 (0.53) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL14846515 0.77 KDM4E (0.51) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL13074842 0.77 ERCC1 (0.41) ERCC1FEN1ERCC4KDM4EHSD17B10
SCHEMBL16622498 0.75 DAO (0.41) ERCC1FEN1ERCC4KDM4EHSD17B10
SCHEMBL5030756 0.74 DAO (0.61) ERCC1FEN1ERCC4KDM4EHSD17B10
SCHEMBL12414070 0.74 HSD17B10 (0.45) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL12506518 0.74 KDM4E (0.54) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL14627848 0.74 LMNA (0.47) KDM4EHSD17B10ALDH1A1HPGDGAA
SCHEMBL4469971 0.74 ALDH1A1 (0.51) KDM4EHSD17B10ALDH1A1POLBKMT2A
SCHEMBL28113666 0.72 ALDH1A1 (0.56) KDM4EALDH1A1GAAKMT2APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1362511-B1 Protective solution for preventing ischaemia KOEHLER CHEMIE DR FRANZ (DE) 2011-03-30 EP claimed
CN-100448440-C Protective solution for preventing local ischemic damage FRANTZ KOLER DR CHEMICAL GMBH (DE) 2009-01-07 CN claimed
CN-1480132-A Protective solution for preventing local ischemic damage �����ġ����ղ�ʿ��ѧ���޹�˾ 2004-03-10 CN claimed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US claimed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP claimed
US-9603354-B2 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2017-03-28 US disclosed
US-7977383-B2 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2011-07-12 US disclosed
EP-1362511-B1 Protective solution for preventing ischaemia KOEHLER CHEMIE DR FRANZ (DE) 2011-03-30 EP disclosed
EP-1859679-B1 Protective solution for preventing ischaemia damage KOEHLER CHEMIE DR FRANZ (DE) 2009-10-28 EP disclosed
CN-100448440-C Protective solution for preventing local ischemic damage FRANTZ KOLER DR CHEMICAL GMBH (DE) 2009-01-07 CN disclosed
EP-1859679-A1 Protective solution for preventing ischaemia damage Dr. Franz Köhler Chemie GmbH (DE) 2007-11-28 EP disclosed
CN-1480132-A Protective solution for preventing local ischemic damage �����ġ����ղ�ʿ��ѧ���޹�˾ 2004-03-10 CN disclosed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US disclosed
EP-1362511-A1 Protective solution for preventing ischaemia Dr. Franz Köhler Chemie GmbH (DE) 2003-11-19 EP disclosed
EP-0030861-A2 Isoquinoline acetic acids and pharmaceutical compositions thereof PFIZER INC. (US) 1981-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030215781-A1 Protective solutions for organs GLS, CA1, SI ERCC1 1660/4885FEN1 1248/4885ERCC4 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.